BioMarin Pharmaceutical Inc.
BMRN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $10 | $11 | $13 | $13 |
| - Cash | $1 | $1 | $1 | $1 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $10 | $10 | $13 | $12 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | -6% | 10.8% | -0.3% | – |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 82% | 81.8% | 79.7% | 81.8% |
| EBITDA | -$0 | $0 | $0 | $0 |
| % Margin | -0.7% | 38.7% | 35.3% | 26.2% |
| Net Income | -$0 | $0 | $0 | $0 |
| % Margin | -4% | 29.1% | 24.9% | 16.7% |
| EPS Diluted | -0.16 | 1.23 | 0.95 | 0.64 |
| % Growth | -113% | 29.5% | 48.4% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |